Serum cystatin C levels are associated with asymptomatic peripheral arterial disease in type 2 diabetes mellitus patients without overt nephropathy

Diabetes Research and Clinical Practice
Ji Hye HuhJang Yel Shin

Abstract

We investigated the association between serum cystatin C and asymptomatic peripheral artery disease (PAD) in type 2 diabetes mellitus patients with normal renal function or mild renal impairment and we compared cystatin C with albuminuria and estimated glomerular filtration rate (eGFR) for prediction of PAD. We enrolled 272 patients with type 2 diabetes. Patients were excluded if they had an eGFR<60mL/min per 1.73m(2), 24-h urine albumin (24h-uAlb)≥300mg/day, serum creatinine (Cr)>1.3mg/dL, or previous history of cardiovascular disease. PAD was defined as having an ankle brachial index (ABI)≤0.9. Patients with PAD were more likely to have a lower eGFR and higher values of 24h-uAlb, cystatin C, and serum Cr than subjects without PAD. Cystatin C was independently associated with age, current smoking, HDL, eGFR, and PAD. Odds ratios (ORs) for PAD after adjustment for age, gender, smoking, and hypertension were 1.71 (95% CI, 1.02-2.85), 1.51 (95% CI, 0.93-2.44), and 0.78 (95% CI, 0.41-1.49) for a one standard deviation increase in cystatin C, 24h-uAlb, and eGFR, respectively. Cystatin C was independently associated with PAD in type 2 diabetes mellitus patients without overt nephropathy.

References

Jul 31, 2001·JAMA : the Journal of the American Medical Association·H C GersteinUNKNOWN HOPE Study Investigators
Jan 20, 2004·Journal of Clinical Laboratory Analysis·Li Hai XiaXia Tie An
May 20, 2005·The New England Journal of Medicine·Michael G ShlipakCatherine Stehman-Breen
Jul 28, 2005·Atherosclerosis·Gérald LucUNKNOWN PRIME Study Group
Aug 16, 2006·Annals of Internal Medicine·Michael G ShlipakDavid S Siscovick
Jan 12, 2008·Atherosclerosis·J ArpegårdP Svensson
Aug 9, 2008·Vascular Medicine·Eric T FungJohn P Cooke
Nov 15, 2008·Journal of the American College of Cardiology·Michael H CriquiArnost Fronek
Mar 24, 2009·Metabolism: Clinical and Experimental·Ming-Chia HsiehShih-Te Tu
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
May 16, 2009·Journal of the American Society of Nephrology : JASN·Toshiharu NinomiyaUNKNOWN ADVANCE Collaborative Group
Feb 4, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·E B JudeN Tentolouris
Dec 17, 2011·Journal of the American Society of Nephrology : JASN·Navdeep TangriMark J Sarnak

❮ Previous
Next ❯

Citations

Jul 5, 2016·Annals of Vascular Diseases
Dec 30, 2015·The International Journal of Lower Extremity Wounds·Janis VellaGodfrey LaFerla
Jun 20, 2019·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Shahab FatemiMoncef Zarrouk
Jan 4, 2021·Annals of Vascular Surgery·Jianqing DengWei Guo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.